<DOC>
	<DOCNO>NCT00207935</DOCNO>
	<brief_summary>This study do see child learn problem learn swallow pill without chew . The reason important person seizure , medication must take every day . Most medication need take 2 3 time per day . Some medication slow release taaken per day . Medications slow release usually come capsule form open chew . This study investiates whether child developmental delay teach swalow pill .</brief_summary>
	<brief_title>Use Sustained Release Antiepileptic Medication ( Depakote速 ER ) Pediatric Epilepsy Mental Retardation/Developmental Disorder Population</brief_title>
	<detailed_description>Participants initially consent study , receive baseline assessment . At baseline visit , seizure type ( partial , primary generalize , secondary generalize ) , seizure focus localization , additional medication treatment status duration study establish . IQ status do ( either school system part developmental assessment , ) use . Behavioral status verify related seizure activity well . Behavioral measure include Vineland ( measure life skill assessment ) Child Behavior Checklist . Participants return study visit two week later . At time initial laboratory test do include trough level valproic acid . Pregnancy test do female childbearing potential , know risk valproic acid pregnancy . Participants return third study visit two week later another trough valproic acid level obtain , effective dosage conversion Depakote速 Sprinkle Depakote速 ER occur . Subsequent study visit occur week 6 8 ( 2 4 week respectively , dose conversion ) ; trough valproic acid level obtain time . At study visit , neurologic ( seizure control ) behavioral status review well monitoring side effect adverse event . Each study visit also include instruction coach regard strategy pill swallow aspect adherence treatment regimen . Compliance ascertain mean drug level monitoring pre post dosage conversion . Clinical global improvement function behavioral issue epilepsy assess . The study conclude 5th visit . Table Events Visit 1 2 3 4 5 Day -28 -14 0 14 28 Week -4 -2 0 2 4 Informed Consent X Eligibility Criteria X X Demographics X Medical Surgical History X IQ verification X QOLIE X X Vineland X X CBCL X X Seizure assessment X X X X X Physical Neurologic exam X X X VS X X X Lab assessment X X</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Intellectual Disability</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>1 . Age 418 year , inclusive . 2 . Clinical Diagnosis Partial Primary Generalized Seizure Disorder 3 . Documented IQ score range borderline , mild , moderate , severe mental retardation ( IQ &lt; 80 ) . 4 . Currently Treatment regimen include Depakote速 Sprinkles either monotherapy adjunctive therapy . Dosages stable least 4 week prior baseline . 5 . Subject 's parent guardian must capable maintaining record dose time , seizure characteristic , adverse event . 1 . Oral Motor Dysfunction degree swallow affect . 2 . History significant aspiration . 3 . Serious medical condition cancer , pancreatitis , diabetes , HIV . 4 . History hepatic dysfunction include history elevate liver enzymes ( AST ALT value great equal three time upper limit normal ) . 5 . History metabolic disorder include urea cycle disorder . 6 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Seizures</keyword>
	<keyword>Depakote</keyword>
	<keyword>Developmental Delay</keyword>
	<keyword>Mental Retardation</keyword>
	<keyword>Swallow</keyword>
</DOC>